Trial Profile
A Multi-Centre Trial Investigating the Long Term Safety and Tolerability of Desmopressin (FE 992026) Orally Disintegrating Tablets for the Treatment of Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Adverse reactions
- Sponsors Ferring Pharmaceuticals
- 14 Sep 2018 Status changed from active, no longer recruiting to completed.
- 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2017 New trial record